UT Health San Antonio, the academic health center of The University of Texas at San Antonio (UT San Antonio) is launching a multi-phase clinical study to better understand how the drug rapamycin may ...

ANN ARBOR, Mich.--(BUSINESS WIRE)--AgelessRx, a leader in longevity telehealth solutions, announced the results of its 12-month, Participatory Evaluation of Aging with Rapamycin for Longevity (PEARL) ...

While vigorous exercise and healthy diets are tried-and-true ways to extend one's lifespan, in recent years, people have turned to prescription drugs with the hope of living a longer, healthier life.

Palvella Therapeutics completed a Phase 3 trial for QTORIN™ rapamycin, targeting a rare genetic disease, with results expected in 2026. Top-line results from the SELVA trial are expected in the first ...

Company remains on track to report top line results from SELVA, a Phase 3 single-arm, baseline-controlled trial evaluating QTORIN™ rapamycin for the treatment of microcystic LMs, in Q1 2026 QTORIN™ ...

Detailed price information for Palvella Therapeutics Inc (PVLA-Q) from The Globe and Mail including charting and trades.

Recent advances in understanding venous malformation disease pathogenesis highlight the PI3K/AKT/mTOR pathway as a key driver of disease proliferation, spurring real-world off-label use of systemic ...

Patent strengthens global intellectual property protection for QTORIN™ rapamycin, Palvella’s lead product candidate from the QTORIN™ platform, in ...